Snail蛋白作为关键转录因子，通过蛋白-蛋白相互作用，与共刺激因子CBP结合，在肿瘤的恶化进程中起关键作用。目前已有Snail抑制剂存在活性低，特异性差等问题；而靶向Snail蛋白，影响Snail/CBP相互作用的抑制剂有望突破当前Snail抑制剂的研究局限。本项目以寻找Snail高亲和力分子，干扰Snail/CBP相互作用为研究策略，以期获得具有全新作用机制Snail抑制剂。前期研究发现，Snail高亲和力化合物cyd19通过抑制Snail/CBP相互作用显示出优异的抗肿瘤活性，但其成药性有待提高。在此基础上，以cyd19为先导物，利用基于结构的药物设计手段，系统地开展对先导物的结构优化和生物活性研究，拓展化合物的多样性。期望在保持化合物高活性的同时提高其成药性，获得有应用前景的Snail抑制剂。本项目的开展将为探索以转录因子Snail为靶标进行抗肿瘤药物研究提供新的思路和借鉴。

As a key transcription factor, Snail protein binds to the costimulatory factor CBP protein through protein-protein interactions and plays a critical role in the progression of tumor progression. However, the reported snail inhibitors have been found to have low activity and poor specificity. But inhibitors that target Snail protein and thus affact the Snail/CBP interactions are expected to break the current research limitations of Snail inhibitors. The purpose of this project is to find Snail inhibitors with a new mechanism of action by finding Snail high-affinity molecules that can interfere the Snail/CBP interaction. In previous studies, cyd19 with high Snail affinity shows excellent anti-tumor activity by inhibiting Snail/CBP interaction, but requires further drugability optimization. Based on the lead cyd19, structure optimization and biological activity will be systematically carried out by using structure-based drug design to expand the chemical diversity and to obtain promising Snail inibitors with desirable druggability and high activity. This project will provide new insights and reference for the anti-tumor drug research targeting the transcription factor Snail protein.